Modern mammography screening and breast cancer mortality: population study

Objective To evaluate the effectiveness of contemporary mammography screening using individual information about screening history and breast cancer mortality from public screening programmes. Design Prospective cohort study of Norwegian women who were followed between 1986 and 2009. Within that period (1995-2005), a national mammography screening programme was gradually implemented, with biennial invitations sent to women aged 50-69 years. Participants All Norwegian women aged 50-79 between 1986 and 2009. Main outcome measures Multiple Poisson regression analysis was used to estimate breast cancer mortality rate ratios comparing women who were invited to screening (intention to screen) with women who were not invited, with a clear distinction between cases of breast cancer diagnosed before (without potential for screening effect) and after (with potential for screening effect) the first invitation for screening. We took competing causes of death into account by censoring women from further follow-up who died from other causes. Based on the observed mortality reduction combined with the all cause and breast cancer specific mortality in Norway in 2009, we used the CISNET (Cancer Intervention and Surveillance Modeling Network) Stanford simulation model to estimate how many women would need to be invited to biennial mammography screening in the age group 50-69 years to prevent one breast cancer death during their lifetime. Results During 15 193 034 person years of observation (1986-2009), deaths from breast cancer occurred in 1175 women with a diagnosis after being invited to screening and 8996 women who had not been invited before diagnosis. After adjustment for age, birth cohort, county of residence, and national trends in deaths from breast cancer, the mortality rate ratio associated with being invited to mammography screening was 0.72 (95% confidence interval 0.64 to 0.79). To prevent one death from breast cancer, 368 (95% confidence interval 266 to 508) women would need to be invited to screening. Conclusion Invitation to modern mammography screening may reduce deaths from breast cancer by about 28%.

[1]  Eugenio Paci,et al.  Summary of the Evidence of Breast Cancer Service Screening Outcomes in Europe and First Estimate of the Benefit and Harm Balance Sheet , 2012, Journal of medical screening.

[2]  P. Glynn,et al.  A stochastic simulation model of U.S. breast cancer mortality trends from 1975 to 2000. , 2006, Journal of the National Cancer Institute. Monographs.

[3]  E. Lynge,et al.  Estimating The Benefits of Mammography Screening: The Impact of Study Design , 2007, Epidemiology.

[4]  E. Paci,et al.  Assessment of the early impact of the population-based breast cancer screening programme in Florence (Italy) using mortality and surrogate measures. , 2002, European journal of cancer.

[5]  Jack Cuzick,et al.  Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women , 1988 .

[6]  Elsebeth Lynge,et al.  Breast cancer mortality in Copenhagen after introduction of mammography screening: cohort study , 2005, BMJ : British Medical Journal.

[7]  D. Berry,et al.  Effect of screening and adjuvant therapy on mortality from breast cancer. , 2006, The New England journal of medicine.

[8]  A. Ellis Breast , 2002, BMJ : British Medical Journal.

[9]  M. Kumle,et al.  Breast cancer mortality in Norway after the introduction of mammography screening , 2013, International journal of cancer.

[10]  A. Miller Screening for breast cancer with mammography , 2001, The Lancet.

[11]  B. Møller,et al.  Breast cancer mortality in participants of the Norwegian Breast Cancer Screening Program , 2013, Cancer.

[12]  Eugenio Paci,et al.  Breast Cancer Mortality in Mammographic Screening in Europe: A Review of Incidence-Based Mortality Studies , 2012, Journal of medical screening.

[13]  J. Skelly,et al.  Comparing screening mammography for early breast cancer detection in Vermont and Norway. , 2008, Journal of the National Cancer Institute.

[14]  L. Vatten,et al.  Understanding recent trends in incidence of invasive breast cancer in Norway: age-period-cohort analysis based on registry data on mammography screening and hormone treatment use , 2012, BMJ : British Medical Journal.

[15]  Peter C Gøtzsche,et al.  Is screening for breast cancer with mammography justifiable? , 2000, The Lancet.

[16]  EUROSCREENWorking Group,et al.  Summary of the evidence of breast cancer service screening outcomes in Europe and first estimate of the benefit and harm balance sheet , 2012 .

[17]  P. Gøtzsche,et al.  Screening for breast cancer with mammography. , 2013, The Cochrane database of systematic reviews.

[18]  M Broeders,et al.  The Impact of Mammographic Screening on Breast Cancer Mortality in Europe: A Review of Trend Studies , 2012, Journal of medical screening.

[19]  Marvin Zelen,et al.  Effect of screening mammography on breast-cancer mortality in Norway. , 2010, The New England journal of medicine.

[20]  Eero Pukkala,et al.  Health effects of obstructive sleep apnoea and the effectiveness of continuous positive airways pressure: a systematic review of the research evidence , 1997, BMJ.

[21]  P. Skaane,et al.  Trends in incidence of ductal carcinoma in situ: the effect of a population-based screening programme. , 2010, Breast.

[22]  Annette Dobson,et al.  Mammography screening and breast cancer mortality in Australia: an aggregate cohort study , 2012, Journal of medical screening.

[23]  C. Pipper,et al.  [''R"--project for statistical computing]. , 2008, Ugeskrift for laeger.

[24]  Ingvar Andersson,et al.  Long-term effects of mammography screening: updated overview of the Swedish randomised trials , 2002, The Lancet.

[25]  Philippe Autier,et al.  Breast cancer mortality in neighbouring European countries with different levels of screening but similar access to treatment: trend analysis of WHO mortality database , 2011, BMJ : British Medical Journal.

[26]  M. Kumle,et al.  Mammography activity in Norway 1983 to 2008 , 2011, Acta oncologica.

[27]  P. Gøtzsche,et al.  Breast cancer mortality in organised mammography screening in Denmark: comparative study , 2010, BMJ : British Medical Journal.

[28]  Angela Mariotto,et al.  Cancer Intervention and Surveillance Modeling Network (CISNET) , 2001, Journal of Investigative Medicine.

[29]  D. Altman,et al.  The benefits and harms of breast cancer screening: an independent review , 2012, British Journal of Cancer.

[30]  P. Skaane,et al.  Overdiagnosis among women attending a population-based mammography screening program , 2013, International journal of cancer.

[31]  Bjørn Møller,et al.  Data quality at the Cancer Registry of Norway: an overview of comparability, completeness, validity and timeliness. , 2009, European journal of cancer.

[32]  Jacques Ferlay,et al.  NORDCAN – a Nordic tool for cancer information, planning, quality control and research , 2010, Acta oncologica.

[33]  J. Castilla,et al.  Changes in breast cancer mortality in Navarre (Spain) after introduction of a screening programme , 2007, Journal of medical screening.

[34]  H. Welch Screening mammography--a long run for a short slide? , 2010, The New England journal of medicine.

[35]  Mike Clarke,et al.  Tamoxifen for early breast cancer: an overview of the randomised trials , 1998, The Lancet.